GlassScriptPhysician profile
Paul S Denker
NPI 1750328811
$17,288.00
in general payments reported to CMS, 2019-2025
67 companies · $2,097 in 2025
The $2,097 reported for 2025 was more than what 77% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,613 · 2020: $1,635 · 2021: $2,722 · 2022: $3,008 · 2023: $3,589 · 2024: $1,624 · 2025: $2,097.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,225 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,225.06 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,642.70 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,541.03 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $1,379.28 | 2019-2024 | |
| Amgen INC. | $1,143.33 | 2019-2025 | Evenity, Otezla, Prolia |
| Astrazeneca Pharmaceuticals LP | $949.62 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $947.69 | 2019-2025 | Jardiance, Ofev |
| Abbott Laboratories | $721.69 | 2019-2025 | Freestyle Libre 2 |
| Xeris Pharmaceuticals, INC. | $610.85 | 2021-2024 | Gvoke Hypopen |
| Mannkind Corporation | $579.55 | 2019-2025 | Afrezza |
| Ibsa Pharma INC. | $553.53 | 2019-2025 | Tirosint, Licart, Tirosint |
| Corcept Therapeutics | $417.66 | 2020-2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $409.18 | 2019-2024 | Cycloset |
| Dexcom, INC. | $394.44 | 2019-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $385.68 | 2022-2025 | |
| Antares Pharma, INC. | $373.90 | 2019-2025 | Xyosted, Nocdurna, Tlando |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $314.68 | 2019-2025 | Unithroid |
| Ucb, INC. | $291.33 | 2024-2025 | Bimzelx, Cimzia |
| Amarin Pharma, INC. | $277.54 | 2019-2022 | |
| Insulet Corporation | $214.25 | 2020-2024 | Omnipod |
| Radius Health, INC. | $209.13 | 2020-2025 | Tymlos |
| Alexion Pharmaceuticals, INC. | $207.73 | 2023-2025 | Strensiq |
| Lifescan, INC. | $189.25 | 2022-2023 | |
| Beta Bionics, INC. | $177.96 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Merck Sharp & Dohme LLC | $175.59 | 2019-2022 | |
| Zealand Pharma US, INC. | $148.06 | 2021-2022 | |
| Nevro Corp. | $139.91 | 2022-2024 | Senza |
| Ultragenyx Pharmaceutical INC. | $137.23 | 2020-2024 | Crysvita, Crysvita |
| Grt US Holding, INC. | $133.06 | 2022 | |
| Astellas Pharma US INC | $123.36 | 2019 | |
| Pfizer INC. | $113.11 | 2021-2023 | |
| Recordati_rare_diseases_inc. | $107.05 | 2023-2025 | Isturisa, Signifor Lar |
| Aurinia Pharma U.S., INC. | $98.18 | 2024-2025 | Lupkynis |
| Abbvie INC. | $84.86 | 2019-2023 | Synthroid |
| Otsuka America Pharmaceutical, INC. | $75.89 | 2023 | Rexulti |
| Novartis Pharmaceuticals Corporation | $69.22 | 2023-2024 | |
| Halozyme INC | $68.22 | 2023 | |
| Embecta Corp. | $56.78 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Horizon Therapeutics Plc | $55.22 | 2023 | Tepezza |
| Acerus Pharmaceuticals Corporation | $49.51 | 2020 | |
| Tandem Diabetes Care, INC. | $45.74 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $44.59 | 2019-2020 | |
| Medtronic, INC. | $44.02 | 2021 | |
| Cequr Corporation | $40.37 | 2023-2024 | Cequr Simplicity |
| Valeritas, INC. | $39.12 | 2019 | |
| Merz Pharmaceuticals, LLC | $38.19 | 2023 | Xeomin |
| Janssen Pharmaceuticals, INC | $38.18 | 2019-2022 | |
| Medtronic Minimed, INC. | $33.55 | 2019-2020 | |
| Exact Sciences Corporation | $32.75 | 2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $32.00 | 2021 | |
| Neurocrine Biosciences, INC. | $30.39 | 2025 | |
| Currax Pharmaceuticals LLC | $28.85 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $27.64 | 2025 | Orencia |
| Ani Pharmaceuticals, INC. | $25.81 | 2025 | Purified Cortrophin Gel |
| Madrigal Pharmaceuticals | $24.64 | 2025 | Rezdiffra |
| Verity Pharmaceuticals INC. | $24.57 | 2025 | Tlando |
| Renalytix Ai, INC. | $22.21 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Shire North American Group INC | $21.28 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $20.73 | 2024 | Evkeeza |
| Kyowa Kirin, INC. | $20.61 | 2023 | Crysvita |
| Vivus LLC | $19.77 | 2022 | |
| Avvisto Therapeutics, LLC | $18.02 | 2024 | Cycloset |
| Ferring Pharmaceuticals INC. | $17.58 | 2019 | |
| Boston Scientific Corporation | $16.00 | 2025 | Intracept |
| Kvk-Tech, INC. | $14.14 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Denker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.